Journal
ANNUAL REVIEW OF CHEMICAL AND BIOMOLECULAR ENGINEERING
Volume 13, Issue -, Pages 325-346Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-chembioeng-092220-030853
Keywords
nanomedicine; brain delivery; brain distribution; brain parenchyma; blood-brain barrier
Categories
Funding
- National Institute of General Medical Sciences [R35GM124677]
Ask authors/readers for more resources
Brain disease is a significant burden, with a high failure rate of drug therapy. Nanotherapeutics offer potential for improving drug delivery to the brain and have shown some success in clinical applications. However, further research is needed for treating neurological disorders and overcoming challenges in nanotherapeutic development.
Brain disease remains a significant health, social, and economic burden with a high failure rate of translation of therapeutics to the clinic. Nanotherapeutics have represented a promising area of technology investment to improve drug bioavailability and delivery to the brain, with several successes for nanotherapeutic use for central nervous system disease that are currently in the clinic. However, renewed and continued research on the treatment of neurological disorders is critically needed. We explore the challenges of drug delivery to the brain and the ways in which nanotherapeutics can overcome these challenges. We provide a summary and overview of general design principles that can be applied to nanotherapeutics for uptake and penetration in the brain. We next highlight remaining questions that limit the translational potential of nanotherapeutics for application in the clinic. Lastly, we provide recommendations for ongoing preclinical research to improve the overall success of nanotherapeutics against neurological disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available